New Drug RK-33 Shows Promise in Treating Breast Cancer

Recent studies highlight significant advancements in cancer treatment, focusing on novel therapies targeting specific cancer types. Researchers at Johns Hopkins Medicine have found that the experimental drug RK-33 shows promise in treating breast cancer with bone metastasis by targeting the protein DDX3, which is prevalent in cancer cells. Meanwhile, scientists in Japan have developed a new culturing method for antitumor bacteria that enhances their cancer-fighting properties, paving the way for innovative bacterial therapies. Additionally, a collaborative effort in Germany has led to the identification and patenting of a promising active substance against gastrointestinal stromal tumors, which often resist standard treatments. This substance has been licensed to a US pharmaceutical company for further development, marking a crucial step toward clinical application. These findings underscore the ongoing efforts to improve cancer therapies and address treatment-resistant tumors.